Matches in SemOpenAlex for { <https://semopenalex.org/work/W95660081> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W95660081 endingPage "173" @default.
- W95660081 startingPage "169" @default.
- W95660081 abstract "Metastatic melanoma is a disease associated with poor prognosis, with a median survival reported to range from 6 to 9 months. Patients who are not candidates for surgical resection have an even worse expected survival. This is largely due to the lack of effective chemotherapeutic regimens and has led to the investigation of alternative treatment strategies including immunotherapy. Although melanoma is felt to be an immunogenic tumor and has been associated with the development of spontaneous tumor-specific immune responses in patients, the implementation of vaccine-based treatment has had limited success. Because the administration of a melanoma-specific vaccine alone has not been sufficient to generate robust and reproducible clinical responses, investigators are currently pursuing additional methods to augment antimelanoma immune responses by optimizing T-cell activation. T-cell activation requires both antigen presentation to the T-cell receptor and a second signal mediated by CD80 and CD86 on antigen-presenting cells and CD28 on the T cell. Ligand binding to CD28 on the T-cell surface leads to T-cell proliferation and expression of activating cytokines such as interleukin-2. Cytotoxic T-lymphocyte antigen-4 (CTLA-4), an inhibitory protein expressed on T cells, competes for the same ligands as CD28 and modulates T-cell activation. Because CTLA-4 has a significantly higher binding efficiency than CD28, CTLA-4 is critical in maintaining immune tolerance to self-antigens and may also limit responses to tumor antigens and vaccine therapy. CTLA-4 blockade either alone or in combination with melanoma-specific vaccines has been explored as a potential means to treat advanced stage melanoma. In this article, we review the spectrum of clinical trials involving CTLA-4 blockade and also review recent correlative studies attempting to elucidate the potential mechanisms by which CTLA-4 blockade achieves its therapeutic effects." @default.
- W95660081 created "2016-06-24" @default.
- W95660081 creator A5033965725 @default.
- W95660081 creator A5047177507 @default.
- W95660081 date "2009-05-01" @default.
- W95660081 modified "2023-10-14" @default.
- W95660081 title "Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma" @default.
- W95660081 cites W1519521580 @default.
- W95660081 cites W1536480181 @default.
- W95660081 cites W1981528932 @default.
- W95660081 cites W2014545440 @default.
- W95660081 cites W2054695890 @default.
- W95660081 cites W2061071534 @default.
- W95660081 cites W2071606715 @default.
- W95660081 cites W2106035269 @default.
- W95660081 cites W2109465910 @default.
- W95660081 cites W2110440135 @default.
- W95660081 cites W2115019377 @default.
- W95660081 cites W2146887062 @default.
- W95660081 cites W2147652122 @default.
- W95660081 cites W2151507811 @default.
- W95660081 cites W2155189639 @default.
- W95660081 cites W2161550811 @default.
- W95660081 cites W2162646864 @default.
- W95660081 doi "https://doi.org/10.1097/ppo.0b013e3181a7450f" @default.
- W95660081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19556898" @default.
- W95660081 hasPublicationYear "2009" @default.
- W95660081 type Work @default.
- W95660081 sameAs 95660081 @default.
- W95660081 citedByCount "51" @default.
- W95660081 countsByYear W956600812012 @default.
- W95660081 countsByYear W956600812013 @default.
- W95660081 countsByYear W956600812014 @default.
- W95660081 countsByYear W956600812016 @default.
- W95660081 countsByYear W956600812018 @default.
- W95660081 countsByYear W956600812023 @default.
- W95660081 crossrefType "journal-article" @default.
- W95660081 hasAuthorship W95660081A5033965725 @default.
- W95660081 hasAuthorship W95660081A5047177507 @default.
- W95660081 hasConcept C147483822 @default.
- W95660081 hasConcept C148125776 @default.
- W95660081 hasConcept C154317977 @default.
- W95660081 hasConcept C202751555 @default.
- W95660081 hasConcept C203014093 @default.
- W95660081 hasConcept C21705690 @default.
- W95660081 hasConcept C2776090121 @default.
- W95660081 hasConcept C2777658100 @default.
- W95660081 hasConcept C2777701055 @default.
- W95660081 hasConcept C2778297628 @default.
- W95660081 hasConcept C2781101188 @default.
- W95660081 hasConcept C39347974 @default.
- W95660081 hasConcept C502942594 @default.
- W95660081 hasConcept C55493867 @default.
- W95660081 hasConcept C71924100 @default.
- W95660081 hasConcept C86803240 @default.
- W95660081 hasConcept C8891405 @default.
- W95660081 hasConceptScore W95660081C147483822 @default.
- W95660081 hasConceptScore W95660081C148125776 @default.
- W95660081 hasConceptScore W95660081C154317977 @default.
- W95660081 hasConceptScore W95660081C202751555 @default.
- W95660081 hasConceptScore W95660081C203014093 @default.
- W95660081 hasConceptScore W95660081C21705690 @default.
- W95660081 hasConceptScore W95660081C2776090121 @default.
- W95660081 hasConceptScore W95660081C2777658100 @default.
- W95660081 hasConceptScore W95660081C2777701055 @default.
- W95660081 hasConceptScore W95660081C2778297628 @default.
- W95660081 hasConceptScore W95660081C2781101188 @default.
- W95660081 hasConceptScore W95660081C39347974 @default.
- W95660081 hasConceptScore W95660081C502942594 @default.
- W95660081 hasConceptScore W95660081C55493867 @default.
- W95660081 hasConceptScore W95660081C71924100 @default.
- W95660081 hasConceptScore W95660081C86803240 @default.
- W95660081 hasConceptScore W95660081C8891405 @default.
- W95660081 hasIssue "3" @default.
- W95660081 hasLocation W956600811 @default.
- W95660081 hasLocation W956600812 @default.
- W95660081 hasOpenAccess W95660081 @default.
- W95660081 hasPrimaryLocation W956600811 @default.
- W95660081 hasRelatedWork W1950726686 @default.
- W95660081 hasRelatedWork W1979857953 @default.
- W95660081 hasRelatedWork W1985394960 @default.
- W95660081 hasRelatedWork W1999675866 @default.
- W95660081 hasRelatedWork W2068757729 @default.
- W95660081 hasRelatedWork W2128810183 @default.
- W95660081 hasRelatedWork W2163213624 @default.
- W95660081 hasRelatedWork W2380183995 @default.
- W95660081 hasRelatedWork W2803643976 @default.
- W95660081 hasRelatedWork W3112764055 @default.
- W95660081 hasVolume "15" @default.
- W95660081 isParatext "false" @default.
- W95660081 isRetracted "false" @default.
- W95660081 magId "95660081" @default.
- W95660081 workType "article" @default.